The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor. RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose. CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of these benefits were consistent regardless of presence or absence of ASCVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondary analyses across several of these trials also showed that HF prevention benefits of SGLT2is are present regardless of baseline CV or antihyperglycemic therapies (including metformin) (Fig. 5).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A comprehensive meta-analysis of 6 major SGLT2i trials in individuals with T2D, comprising nearly 50,000 participants showed a 32% reduction in the risk of hospitalization for HF (HR, 0.68; 95% CI, 0.61–0.76), a 22% reduction in the composite of hypertensive HF and CV death (HR, 0.78; 95% CI, 0.73–0.84), and a 15% reduction in CV death (HR, 0.85; 95% CI, 0.78–0.93) with SGLT2is vs placebo.649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, there was also a modest but significant 10% reduction in the risk of MACE (HR, 0.90; 95% CI, 0.85–0.95).649”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [649]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (309,312).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the relatively small percentage of such individuals enrolled (only 21% of participants had ejection fraction >50%) and the early termination of the trial limited the ability to determine the effects of sotagliflozin in HFpEF specifically (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there were low rates of ketoacidosis in the cardiovascular and heart failure outcomes trials evaluating SGLT inhibition, these studies excluded individuals with type 1 diabetes and/or recent history of diabetic ketoacidosis (296,298).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies that led to the approved indication for heart failure (HF) excluded individuals with type 1 diabetes or a history of DKA (82,83).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sotagliflozin significantly reduced the risk of achieving the primary end point of CV death, HHF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67 [95% CI 0.52-0.85]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“There was no signi fi cant interaction by eGFR status for the primary outcome.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“sotaglifl ozin did reduce the primary outcome by 33% (HR: 0.67; 95% CI: 0.52 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“In the SOLOIST trial, sotagliflozin initiated during or shortly after hospitalization in people with diabetes also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (309).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“ultimately no evidence of heterogeneity of treatment effect by ejection fraction was noted.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [309]
The cited source says what the claim attributes to it.
In the citing paper
“In the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial, sotagliflozin, a combined SGLT1/2 inhibitor, initiated during or shortly after hospitalization for heart failure in people with diabetes, also reduced the risk for the primary end point of deaths from cardiovascular causes and hospitalizations and urgent visits”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [296]
In the citing paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [12]
In the citing paper
“Sotagliflozin reduced the risk of the primary composite outcome of CV death, HF hospitalization, and urgent visit for HF by 33%, with a consistent effect across the spectrum of baseline LVEF.However, the number of events in the HFpEF group was too small to draw any firm conclusion.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sotagliflozin significantly reduced the RR of the composite primary outcome (CV death, HF hospitalization, or urgent visit for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52-0.85).The treatment effect was consistent across the spectrum of LVEF.189”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“Sub-group analyses considering those co-prescribed MRA and SGLT2 inhibitors suggest their combined use does not modify safety findings from the key trials.150,189,[722][723][724][725][726]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [189]
In the citing paper
“However, the relatively small percentage of such patients enrolled (only 21% of participants had ejection fraction > 50%) and the early termination of the trial limited the ability to determine the effects of sotagli fl ozin in HFpEF speci fi cally.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“No signi fi cant between-group differences were found in the rates of cardiovascular death or all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
In the citing paper
“At a median follow-up of 9 months, the rate of primary end point events (the total number of cardiovascular deaths and hospitalizations and urgent visits for heart failure) was lower in the sotaglifl ozin group than in the placebo group (51.0 vs. 76.3; HR 0.67 [95% CI 0.52 -0.85]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [228]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Flagged first, then by citations
Research works printed but not linked: 1
- Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132(15):e198-e198.26459088
Cited by
Sorted by citations
Items 501–600 of 1,000
Kidney Considerations in Pediatric Obesity
Sawyer, A., Zeitler, E. M., Trachtman, H., & Bjornstad, P. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00522-3 · Cited by 23
Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Ali, A. E., Mazroua, M. S., ElSaban, M., Najam, N., Kothari, A. S., Mansoor, T., Amal, T., Lee, J., & Kashyap, R. (2023) · Global Heart · doi:10.5334/gh.1258 · Cited by 22
Oskouie, S. K., Pandey, A., Sauer, A. J., Greene, S. J., Müllens, W., Khan, M. S., Quinn, K. L., Ho, J. E., Albert, N. M., & Spall, H. G. C. V. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101131 · Cited by 25
Martinez, C. S., Zheng, A., & Xiao, Q. (2024) · Antioxidants · doi:10.3390/antiox13111330 · Cited by 26
Brata, R. D., Paşcalău, A. V., Frățilă, O., Paul, I. L., Muresan, M. M., Cămărășan, A., & Ilias, T. I. (2024) · Healthcare · doi:10.3390/healthcare12232464 · Cited by 21
Worsening heart failure: progress, pitfalls, and perspectives
Fonseca, C., Rui, B., Franco, F., Brenda, M., Pimenta, J., Sarmento, P., Silva‐Cardoso, J., & Brito, D. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10497-z · Cited by 24
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
Self-citationAristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 24
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 28
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 21
Janjusevic, M., Fluca, A. L., Gagno, G., Pierri, A., Padoan, L., Sorrentino, A., Beltrami, A. P., Sinagra, G., & Aleksova, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042336 · Cited by 21
Improving implementation of evidence‐based therapies for heart failure
DeVore, A. D., Bosworth, H. B., & Granger, B. B. (2022) · Clinical Cardiology · doi:10.1002/clc.23845 · Cited by 22
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Lewis, R., Jovkovic, M., Zieroth, S. R., O’Meara, E., Connelly, K. A., & Sherifali, D. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.011 · Cited by 21
Minciunescu, A., Genovese, L. D., & deFilippi, C. R. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01347-2 · Cited by 21
Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure
Lameire, N. H. (2023) · Kidney and Dialysis · doi:10.3390/kidneydial3010005 · Cited by 21
Treewaree, S., Kulthamrongsri, N., Owattanapanich, W., & Krittayaphong, R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1046194 · Cited by 21
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 22
Park, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0016 · Cited by 21
Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Andersen, K. R., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2990 · Cited by 21
Self-citationThe current best drug treatment for hypertensive heart failure with preserved ejection fraction
Rist, A., Sevre, K., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.008 · Cited by 23
Self-citationSpot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
Guzik, M., Iwanek, G., Fudim, M., Zymliński, R., Marciniak, D. M., Ponikowski, P. P., & Biegus, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-51744-x · Cited by 21
Self-citationEmerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 22
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21
Singh, A. K., & Singh, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.01.006 · Cited by 21
Diabetes Management in Patients with Heart Failure
Shen, J., & Greenberg, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0296 · Cited by 21
Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
Delanaye, P., Wissing, K. M., & Scheen, A. J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab096 · Cited by 21
Young, S. L., Ryan, L., MULLINS, T. P., Flint, M., Steane, S. E., Walton, S. L., Bielefeldt‐Ohmann, H., Carter, D. A., Reichelt, M. E., & Gallo, L. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738594 · Cited by 21
Li, Y., & Xu, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106049 · Cited by 21
Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
Cappetta, D., Angelis, A. D., Bellocchio, G., Telesca, M., Cianflone, E., Torella, D., Rossi, F., Urbanek, K., & Berrino, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.810791 · Cited by 21
Reyes-Farias, C. I., Reategui-Diaz, M., Romani-Romani, F., & Prokop, L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295059 · Cited by 20
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 21
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 24
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O. D., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 23
Self-citationCoronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Srivastava, S. P., Srivastava, R., Chand, S., & Goodwin, J. E. (2021) · Pharmaceuticals · doi:10.3390/ph14080751 · Cited by 20
Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
Rahamim, E., Nachman, D., Yagel, O., Yarkoni, M., Elbaz‐Greener, G., Amir, O., & Asleh, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194409 · Cited by 21
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction
Greenberg, B. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0401 · Cited by 20
Yang, D., Zhang, Y., Yan, J. R., Liu, M. R., & An, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.942125 · Cited by 21
Okoroike, H., Patel, S., Simone, P. B., Lavelle, R. I., & Szwak, J. A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.09.019 · Cited by 20
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 21
Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium
Amesz, J. H., Langmuur, S. J. J., Epskamp, N., Bogers, A. J. J. C., de Groot, N. M. S., Manintveld, O. C., & Taverne, Y. J. H. J. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07434-3 · Cited by 20
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 25
Wang, Y., Hou, R., Ni, B., Jiang, Y. P., & Zhang, Y. (2023) · Clinical Cardiology · doi:10.1002/clc.24104 · Cited by 23
Leiter, L. A., Bhatt, D. L., McGuire, D. K., Teoh, H., Fox, K. M., Simon, T., Mehta, S. R., Lev, E. I., Kiss, R. G., Dalby, A. J., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.298 · Cited by 21
Self-citationQiu, M., Zhao, L., & Zhan, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.743807 · Cited by 20
Koufakis, T., Mustafa, O. G., Ajjan, R., García–Moll, X., Zebekakis, P. E., Dimitriadis, G., & Kotsa, K. (2022) · Drugs · doi:10.1007/s40265-022-01730-2 · Cited by 20
RADAKRISHNAN, A., AGRAWAL, S., SINGH, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.008 · Cited by 19
Managing the side effects of sodium-glucose cotransporter-2 inhibitors
Kodur, N., Sharew, B., Lansang, M. C., & Tang, W. H. W. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24071 · Cited by 19
Anker, S. D., Khan, M. S., Shahid, I., Filippatos, G. S., Coats, A. J. S., & Butler, J. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2279 · Cited by 19
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
Cho, I., & Kang, S. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.900 · Cited by 19
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Heath, R., Johnsen, H. S., Strain, W. D., & Evans, M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01204-4 · Cited by 20
Patoulias, D., Fragakis, N., & Rizzo, M. (2022) · Life · doi:10.3390/life12122062 · Cited by 19
Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 20
Getting ahead of the game: in-hospital initiation of HFrEF therapies
Biegus, J., Moayedi, Y., Saldarriaga, C., & Ponikowski, P. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac120 · Cited by 19
Self-citationOstrominski, J. W., & Vaduganathan, M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.035 · Cited by 21
Pérez, M. S., Rodríguez‐Capitán, J., Requena-Ibáñez, J. A., Santos‐Gallego, C. G., Zafar, M. U., Escolar, G., MANCINI, D. M., Mitter, S. S., Lam, D. W.-H., Contreras, J., et al. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07469-6 · Cited by 19
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Matthews, J. R., Herat, L. Y., Schlaich, M. P., & Matthews, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814243 · Cited by 19
Jeon, J. Y., & Kim, D. J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0317 · Cited by 19
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 21
Self-citationGao, F. M., Ali, A. S., Bellomo, R., Gaca, M., Lecamwasam, A., Churilov, L. P., & Ekinci, E. I. (2024) · Diabetes Care · doi:10.2337/dc24-0946 · Cited by 19
Ritsinger, V., Hagström, E., Lagerqvist, B., & Norhammar, A. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022667 · Cited by 19
Wang, A., Li, Z., Zhuo, S., Gao, F., Zhang, H., Zhang, Z., Ren, G., & Ma, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.857952 · Cited by 19
Ducharme, A., Zieroth, S. R., Ahooja, V., Anderson, K., Andrade, J. G., Boivin‐Proulx, L., Ezekowitz, J. A., Howlett, J. G., Lepage, S., Leong, D., et al. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.04.022 · Cited by 19
Butler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab704 · Cited by 18
Endpoint adjudication in cardiovascular clinical trials
Khan, M. S., Usman, M., Spall, H. G. C. V., Greene, S. J., Baqal, O. J., Felker, G. M., Bhatt, D. L., Januzzi, J. L., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad718 · Cited by 18
Self-citationChristodorescu, R., Geavlete, O. D., Ferrini, M., Kümler, T., Toutoutzas, K., Bayés‐Genís, A., Seferovic, P. M., Metra, M., Chioncel, O., Rosano, G. M. C., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3444 · Cited by 18
Self-citationPham, L. T. T., Mangmool, S., & Parichatikanond, W. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00240 · Cited by 19
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Trask-Marino, A. L., Marino, B., Lancefield, T. F., See, E. J., May, C. N., Booth, L. C., Raman, J., & Lankadeva, Y. R. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2024 · Cited by 19
Cherbi, M., Lairez, O., Baudry, G., Gautier, P., Roubille, F., & Delmas, C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039105 · Cited by 18
SGLT2 inhibitors and acute kidney injury
Nakao, Y., Mori, M., Mori, Y., & Bonventre, J. V. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf132 · Cited by 18
Fisk, M., Althage, M., Moosmang, S., Greasley, P. J., Cope, A. P., Jayne, D. R. W., Galloway, J. B., Hall, F. C., Wilkinson, I. B., Ambery, P., et al. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102035 · Cited by 18
Congestion in Patients with Advanced Heart Failure
Lombardi, C., Cimino, G., Pellicori, P., Bonelli, A., Inciardi, R. M., Pagnesi, M., Tomasoni, D., Ravera, A., Adamo, M., Carubelli, V., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.003 · Cited by 18
Self-citationDocherty, K. F., Anand, I. S., Chiang, C., Chopra, V., Desai, A. S., Kitakaze, M., Verma, S., Vinh, P. N., Inzucchi, S. E., Køber, L., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.02.004 · Cited by 18
Self-citationSodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: An Updated Meta-Analysis
Cao, Y., Li, P., Li, Y., & Han, Y. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13905 · Cited by 18
Latent autoimmune diabetes in adults in China
Qiu, J., Xiao, Z., Zhang, Z., Luo, S., & Zhou, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977413 · Cited by 19
Chen, G., Shen, S., Zhang, K., Zhou, L., Shen, J., Zhao, J., Ding, S.-G., Ma, L., & Gao, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.926979 · Cited by 18
Herat, L. Y., Matthews, J. R., Hibbs, M. E., Rakoczy, E. P., Schlaich, M. P., & Matthews, V. B. (2022) · iScience · doi:10.1016/j.isci.2023.107260 · Cited by 18
Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
Chen, X., Wang, J., Lin, Y., Yao, K., Xie, Y., & Zhou, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236404 · Cited by 18
Kongmalai, T., Hadnorntun, P., Leelahavarong, P., Kongmalai, P., Srinonprasert, V., Chirakarnjanakorn, S., Chaikledkaew, U., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216160 · Cited by 18
Nodirahon, A., Majid, H., Waghdhare, S., Vohora, D., & Agarwal, N. B. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101555 · Cited by 18
Hiraiwa, H., Okumura, T., & Murohara, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00641-9 · Cited by 19
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Galis, P., Bartosova, L., Farkašová, V., Barteková, M., Ferenczyová, K., & Rajtík, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451100 · Cited by 19
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 18
Grewal, D., Partow-Navid, R., Garcia, D., Coney, J., Fraser, G. E., Stoletniy, L. N., Sakr, A. E., Parwani, P. J., & Abramov, D. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.04.017 · Cited by 18
Alkabbani, W., & Gamble, J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281602 · Cited by 18
Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
Gómez‐Pérez, A. M., Damas-Fuentes, M., Cornejo-Pareja, I. M., & Tinahones, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194497 · Cited by 18
Borovac, J. A., Kurir, T. T., Mustapić, I., Kumrić, M., Božić, J., Glavaš, D., & D’Amario, D. (2022) · Kardiologia Polska · doi:10.33963/kp.a2021.0172 · Cited by 18
Giaccari, A., Pontremoli, R., & Filardi, P. P. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.050 · Cited by 18
Kidney function assessment and endpoint ascertainment in clinical trials
Khan, M. S., Bakris, G. L., Packer, M., Shahid, I., Anker, S. D., Fonarow, G. C., Wanner, C., Weir, M. R., Zannad, F. M., & Butler, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab832 · Cited by 19
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 19
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 18
Fu, M. L. X., & Swedberg, K. B. (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000073 · Cited by 17
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 18
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3440 · Cited by 19
Self-citationShokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
The effects of antidiabetic agents on heart failure
Wijnen, M., Duschek, E. J. J., Boom, H., & van Vliet, M. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01579-2 · Cited by 17
Rasalam, R. R., Atherton, J. J., Deed, G., Molloy‐Bland, M., Cohen, N. D., & Sindone, A. P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13483 · Cited by 17
New Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 17
Self-citationKoufakis, T., Giannakoulas, G., Zebekakis, P. E., & Kotsa, K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2003329 · Cited by 17
Metadata
- Authors
- Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Verma, S., Lapuerta, P., & Pitt, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); State University of New York Downstate School of Public Health, Brooklyn (M.S.); Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148 ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 117-128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3100542962
- Semantic Scholar
- a022df46be992be653dc8f2439f324470b7eb318
- Cited by
- 1,868
- References
- 51
- Citations by year
- 2026: 160 · 2025: 231 · 2024: 316 · 2023: 373 · 2022: 409 · 2021: 355
- FWCI
- 178.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Sanofi
- Lexicon Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- sotagliflozin, SGLT2 inhibitors, type 2 diabetes, worsening heart failure, acute decompensated heart failure, heart failure hospitalization, cardiovascular mortality, diarrhea, hypoglycemia, drug safety, DAPA-HF
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycosides, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Sodium-Glucose Transporter 1, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
